Clinical efficacy and safety of cyclosporine A in the treatment of patients with unexplained recurrent implantation failure
Objective To explore the clinical efficacy and safety of cyclosporin A(CsA)in the treatment of patients with unexplained repeated/recurrent implantation failure(RIF).Methods 101 patients with unexplained RIF who received treatment in Zaozhuang Maternal and Child Health Hospital from March 2021 to December 2022 were selected as the study objects,and were divided into control group(n=51,conventional treatment)and observation group(n=50,conventional treatment+CsA)according to the numerical ranking table method.The live birth rate,clinical pregnancy rate,embryo implantation rate,abortion rate,immune index,incidence of pregnancy complications,adverse drug reactions and neonatal conditions were compared between the two groups.Results The live birth rate,clinical pregnancy rate and embryo implantation rate of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).But there were no significant differences in the abortion rate between the two groups(P>0.05).After treatment with CsA,the value of tumor necrosis factor(TNF-α)decreased in the observation group after transplantation,while the value of interleukin-10(IL-10)increased.Compared with the control group,the difference was statistically significant(P<0.05).There were no significant differences in pregnancy complications,adverse fetal conditions,physical growth and development of offspring within 1 year after delivery and DDST Denver development screening between the two groups(P>0.05).Conclusion The treatment of patients with unexplained RIF with CsA can improve the live birth rate,clinical pregnancy rate,embryo implantation rate and reduce pregnancy abortion,but does not increase the risk of pregnancy complications,fetal adverse pregnancy and abnormal development of offspring.